Temporal trends in acute stroke management.
作者信息
Kleindorfer Dawn, de los Rios La Rosa Felipe, Khatri Pooja, Kissela Brett, Mackey Jason, Adeoye Opeolu
机构信息
University of Cincinnati, 260 Stetson Street, Cincinnati, OH 45267, USA.
出版信息
Stroke. 2013 Jun;44(6 Suppl 1):S129-31. doi: 10.1161/STROKEAHA.113.001457.
Abstract
摘要
相似文献
1
Temporal trends in acute stroke management.急性卒中管理的时间趋势。
Stroke. 2013 Jun;44(6 Suppl 1):S129-31. doi: 10.1161/STROKEAHA.113.001457.
2
Can we extend thrombolysis indications for acute ischaemic stroke? The IST-3 study.我们能否扩大急性缺血性卒中的溶栓适应症？IST-3研究。
Intern Emerg Med. 2013 Apr;8(3):261-2. doi: 10.1007/s11739-012-0899-1. Epub 2013 Mar 1.
3
Thrombolysis with tissue plasminogen activator: protocol violation is not an option.
Neurol India. 2007 Apr-Jun;55(2):174; author reply 174-5. doi: 10.4103/0028-3886.32797.
4
Breaking up is hard to do: tenecteplase in acute stroke.分手不易：急性卒中中的替奈普酶
Lancet Neurol. 2015 Apr;14(4):343-5. doi: 10.1016/S1474-4422(15)70036-0. Epub 2015 Feb 26.
5
United States trends in thrombolysis for older adults with acute ischemic stroke.美国老年急性缺血性卒中患者溶栓治疗的趋势。
Clin Neurol Neurosurg. 2015 Dec;139:16-23. doi: 10.1016/j.clineuro.2015.08.031. Epub 2015 Sep 10.
6
Feasibility and safety of intravenous thrombolysis for acute ischaemic stroke in northern Greece.希腊北部急性缺血性脑卒中静脉溶栓治疗的可行性与安全性
Int J Stroke. 2011 Feb;6(1):91-2. doi: 10.1111/j.1747-4949.2010.00547.x.
7
Should right-to-left shunts be detected before thrombolysis in acute ischemic stroke patients?
Stroke. 2009 Feb;40(2):e29; author reply e32. doi: 10.1161/STROKEAHA.108.540047. Epub 2008 Dec 18.
8
[The treatment of acute ischemic stroke].[急性缺血性卒中的治疗]
Orv Hetil. 2004 Nov 7;145(45):2297-301.
9
Thrombolysis for acute ischemic stroke.急性缺血性脑卒中的溶栓治疗。
Curr Top Med Chem. 2009;9(14):1285-90. doi: 10.2174/156802609789869655.
10
Stroke: thrombolysis in childhood arterial ischemic stroke.中风：儿童急性动脉缺血性中风的溶栓治疗。
Nat Rev Neurol. 2009 Sep;5(9):473-4. doi: 10.1038/nrneurol.2009.130.
引用本文的文献
1
BMSCs-derived small extracellular vesicles antagonize cerebral endothelial Caveolin-1 driven autophagic degradation of tight-junction proteins to protect blood-brain barrier post-stroke.骨髓间充质干细胞衍生的小细胞外囊泡可拮抗脑内皮细胞中窖蛋白-1驱动的紧密连接蛋白自噬降解，从而在中风后保护血脑屏障。
Int J Biol Sci. 2025 Jan 1;21(2):842-859. doi: 10.7150/ijbs.101937. eCollection 2025.
2
Exosome-Coated tPA/Catalase Nanoformulation for Thrombolytic Therapy.用于溶栓治疗的外泌体包被的组织型纤溶酶原激活剂/过氧化氢酶纳米制剂
Bioengineering (Basel). 2023 Jan 31;10(2):177. doi: 10.3390/bioengineering10020177.
3
Efficacy of novel SPAK inhibitor ZT-1a derivatives (1c, 1d, 1g & 1h) on improving post-stroke neurological outcome and brain lesion in mice.新型 SPAK 抑制剂 ZT-1a 衍生物（1c、1d、1g 和 1h）在改善小鼠中风后神经功能预后和脑损伤中的作用。
Neurochem Int. 2023 Jan;162:105441. doi: 10.1016/j.neuint.2022.105441. Epub 2022 Nov 11.
4
Thrombolytic tPA-induced hemorrhagic transformation of ischemic stroke is mediated by PKCβ phosphorylation of occludin.血栓溶解 tPA 诱导的缺血性中风出血性转化是由 occludin 的蛋白激酶 Cβ磷酸化介导的。
Blood. 2022 Jul 28;140(4):388-400. doi: 10.1182/blood.2021014958.
5
Heparin and Arginine Based Plasmin Nanoformulation for Ischemic Stroke Therapy.肝素和精氨酸基纤溶酶原纳米制剂治疗缺血性脑卒中。
Int J Mol Sci. 2021 Oct 25;22(21):11477. doi: 10.3390/ijms222111477.
6
MicroRNA-424 alleviates neurocyte injury by targeting PDCD4 in a cellular model of cerebral ischemic stroke.在脑缺血性中风细胞模型中，微小RNA-424通过靶向程序性细胞死亡蛋白4减轻神经细胞损伤。
Exp Ther Med. 2021 Dec;22(6):1453. doi: 10.3892/etm.2021.10888. Epub 2021 Oct 15.
7
Association between Area-Level Socioeconomic Deprivation and Prehospital Delay in Acute Ischemic Stroke Patients: An Ecological Study.基于人群的研究：地区社会经济剥夺与急性缺血性脑卒中患者院前延误的关系。
Int J Environ Res Public Health. 2020 Oct 11;17(20):7392. doi: 10.3390/ijerph17207392.
8
Modulation of brain cation-Cl cotransport via the SPAK kinase inhibitor ZT-1a.通过 SPAK 激酶抑制剂 ZT-1a 调节脑阳离子-Cl 共转运体。
Nat Commun. 2020 Jan 7;11(1):78. doi: 10.1038/s41467-019-13851-6.
9
Erratum: Contraindications to intravenous rtPA for acute stroke: A critical reappraisal.勘误：急性卒中静脉注射重组组织型纤溶酶原激活剂的禁忌证：一项批判性重新评估。
Neurol Clin Pract. 2013 Oct;3(5):371. doi: 10.1212/01.CPJ.0000435706.04846.53.
10
miR-148b Regulates Proliferation and Differentiation of Neural Stem Cells via Wnt/β-Catenin Signaling in Rat Ischemic Stroke Model.在大鼠缺血性中风模型中，miR-148b通过Wnt/β-连环蛋白信号通路调节神经干细胞的增殖和分化。
Front Cell Neurosci. 2017 Oct 20;11:329. doi: 10.3389/fncel.2017.00329. eCollection 2017.
本文引用的文献
1
Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.人群中静脉注射重组组织型纤溶酶原激活剂的适应证：欧洲合作急性脑卒中研究（ECASS）III 试验的影响。
Stroke. 2012 Jun;43(6):1591-5. doi: 10.1161/STROKEAHA.111.645986. Epub 2012 Mar 22.
2
Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.美国重组组织型纤溶酶原激活物治疗缺血性脑卒中：5 年内治疗率翻一番。
Stroke. 2011 Jul;42(7):1952-5. doi: 10.1161/STROKEAHA.110.612358. Epub 2011 Jun 2.
3
US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke.美国医院对急性缺血性中风使用重组组织型纤溶酶原激活剂（rt-PA）的地理分布情况。
Stroke. 2009 Nov;40(11):3580-4. doi: 10.1161/STROKEAHA.109.554626. Epub 2009 Oct 1.
4
Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.静脉注射组织型纤溶酶原激活剂治疗急性缺血性卒中时间窗的扩展：美国心脏协会/美国卒中协会的科学建议
Stroke. 2009 Aug;40(8):2945-8. doi: 10.1161/STROKEAHA.109.192535. Epub 2009 May 28.
5
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.急性缺血性卒中发病3至4.5小时后使用阿替普酶进行溶栓治疗。
N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.
6
National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.美国全国重组组织型纤溶酶原激活剂使用情况的估计：国际疾病分类第九版编码严重低估。
Stroke. 2008 Mar;39(3):924-8. doi: 10.1161/STROKEAHA.107.490375. Epub 2008 Jan 31.
7
Population-based analysis of the impact of expanding the time window for acute stroke treatment.基于人群的急性卒中治疗时间窗扩大影响分析。
Stroke. 2007 Dec;38(12):3213-7. doi: 10.1161/STROKEAHA.107.491852. Epub 2007 Oct 25.
8
Emergency department arrival times after acute ischemic stroke during the 1990s.20世纪90年代急性缺血性卒中后的急诊科到达时间。
Neurocrit Care. 2007;7(1):31-5. doi: 10.1007/s12028-007-0029-5.
9
Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.急性缺血性卒中患者使用重组组织型纤溶酶原激活剂的适用性：一项基于人群的研究。
Stroke. 2004 Feb;35(2):e27-9. doi: 10.1161/01.STR.0000109767.11426.17. Epub 2004 Jan 22.
10
Tissue plasminogen activator for acute ischemic stroke.用于急性缺血性卒中的组织型纤溶酶原激活剂
N Engl J Med. 1995 Dec 14;333(24):1581-7. doi: 10.1056/NEJM199512143332401.
Zotero 插件